
R&D Services
Our R&D Services offer


Flow Chemistry

Computational predictive toxicology and mechanism of action investigation

Multi-catalysis

Late Phase development for pharmaceutical solutions

Early Phase development for pharmaceutical solutions

Custom ingredients

Cosmetics & Personal care

High-Potency APIs (HPAPIs)

Solid state characterization

Artificial Intelligence

Toxicology

Aramon’Lab (Drug Delivery Polymers)

Biocatalysis

Applicative R&D
#News
Seqens to Unveil New Innovation and Development Center of Excellence
Seqens, an integrated global leader in pharmaceutical synthesis and specialty ingredients, will open a 34,000-square-meter lab today that is close to Paris…
Read moreSeqens’Lab Unveiling
Seqens is unveiling its main innovation and development centre in the presence of Ms. Agnès Pannier-Runacher, Secretary of State to the Minister…
Read moreCOVID-19: SEQENS mobilizes its innovation department
Pending the availability of a vaccine, which will necessarily take time, the race against the clock is underway for the identification and…
Read morePorcheville obtained its GMP certificate
SEQENS R&D Center in Porcheville, France, confirms its status as a center of excellence On 21 January 2019, the French National Agency for…
Read moreApplying Enzymatic Synthesis for Chiral Molecules
Pharma’s Almanac Magazine Advances in our understanding of enzymatic transformations and the increased availability of enzymes engineered for use in fine chemical synthesis…
Read moreGenEvolution: awarded at the “Entrepreneur Prize” trophies
On the evening of Tuesday, March 19, 2019, GenEvolution, based at the Porcheville Seqens site, received two awards: the Public Prize and the Innovation…
Read moreLubricant: interview of Christelle FERRAGUT & Guillaume NOTHEAUX
Lubricant additives & grease at Seqens “We do not sell a molecule, we sell a performance.” How much do you know Lubricant…
Read moreCovid-19: the benefits of flow chemistry & biocatalysis
Efficient and safe process design combining SEQENS technical capabilities: Brilacidin as a case study As already mentioned in our previous article (“Seqens…
Read more